Physician profile
Adam M Paddock
NPI 1598827099
$2,545.94
in general payments reported to CMS, 2019-2025
20 companies · $631 in 2025
The $631 reported for 2025 was more than what 83% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $219 · 2020: $200 · 2021: $239 · 2022: $327 · 2023: $212 · 2024: $718 · 2025: $631.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,562.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,561.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaukos Corporation | $404.89 | 2021-2025 | Photrexa Viscous and Photrexa, Istent Trabecular Micro-Bypass System Model Is3 |
| Alcon Vision LLC | $366.12 | 2022-2025 | Rocklatan, Precision7, Tryptyr |
| Bausch & Lomb Americas INC. | $357.29 | 2022-2025 | Miebo, Xiidra, Infuse |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $239.53 | 2019-2021 | |
| Sun Pharmaceutical Industries INC. | $171.87 | 2022-2024 | Cequa |
| Oyster Point Pharma, INC. | $144.72 | 2022-2025 | Tyrvaya, Ryzumvi |
| Abbvie INC. | $139.08 | 2022-2024 | |
| Optos, INC. | $139.03 | 2020 | |
| Tarsus Pharmaceuticals, INC. | $115.83 | 2024 | Xdemvy |
| Harrow Eye, LLC | $84.16 | 2024-2025 | Vevye |
| Genentech USA, INC. | $63.68 | 2019 | |
| Dompe US, INC. | $63.47 | 2025 | Oxervate |
| Allergan, INC. | $63.45 | 2020-2021 | |
| Johnson & Johnson Vision Care, INC. | $41.03 | 2019-2022 | |
| Astellas Pharma Global Development | $31.57 | 2024 | Izervay |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coopervision INC. | $31.40 | 2024 | Clariti Contact Lens, Myday Contact Lens |
| Novartis Pharmaceuticals Corporation | $29.75 | 2022-2023 | |
| Aerie Pharmaceuticals, INC. | $22.43 | 2019 | |
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Carl Zeiss Meditec, INC. | $17.24 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Adam Paddock listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.